Home › Diabetic Eye Problems › NCT07222293
Assessment of AI Program 'DRISTi' as a Screening Tool
Assessment of 'DRISTi' as an Automated Diabetic Retinopathy Screening Tool in Diabetic Populations
Who can join
Ages 21 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: 1. Ability to sign and date the informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Age (≥)21 years of age or older 4. Diagnosed with diabetes mellitus as per criteria established by the World Health Organization (WHO) or the American Diabetes Association (ADA) 1. Hemoglobin A1c (HbA1c) ≥ 6.5% 2. Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) 3. Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L) Exclusion Criteria: 1. Persistent visual impairment in one or both eyes; 2. History of macular edema or retinal vascular (vein or artery) occlusion; 3. History of ocular injections, laser treatment of the retina, or intraocular surgery other than cataract surgery without complications; 4. Subject is contraindicated for fundus photography (for example, has light sensitivity); 5. Subject has contraindications for mydriatic medications or is unwilling or unable to dilate; 6. Subject is currently enrolled in an interventional study of an investigational device or drug for the same condition; or 7. Subject has a condition or is in a situation which in the opinion of the Investigator, might confound study results, may interfere significantly with the subject's participation in the study, or may result in ungradable clinical reference standard photographs 8. Subject falls into one of the below categories: * Adults unable to consent (individuals w/ impaired decision-making capacity) * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners
About the study
A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and will consent to have ophthalmic images taken. These images will be analyzed by DRISTi AI software and evaluated by an ophthalmic reading center. The results will be compared, and a statistical analysis will be completed to ensure statistical significance in the outcomes thus proving DRISTi is an effective DR diagnosis tool.
What is being tested
- Fundus Image Grading (diagnostic test)
Sponsor: Artelus AI · Participants: 900 · Started: Nov 23, 2025
Contact the study team
- Jeanne Champion, Primary Site Coordinator Oxford · Phone: 9192347003
- Adriana Valencia, Site Coordinator Raleigh · Phone: 9192347406
Official record on ClinicalTrials.gov — NCT07222293
Locations in the U.S.
| North Carolina | New Century Ophthalmology - Oxford, Oxford New Century Ophthalmology - Raleigh, Raleigh |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.